March 30, 2005 10:54 ET

Newly Published Study Shows Growing Medical Acceptance of Statin Drug Usefulness in Treatment of Dementia




MARCH 30, 2005 - 10:54 ET

Newly Published Study Shows Growing Medical Acceptance
of Statin Drug Usefulness in Treatment of Dementia

MAYWOOD, N.J.--(CCNMatthews - Mar 30, 2005) -

Nymox Has Global Patent Rights for Statin Drugs for the Treatment
and Prevention of Alzheimer's Disease

Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) U.S. and global patent
rights and prospects for the use of statin drugs for treating,
preventing or reducing the risk of Alzheimer's disease (AD) in patients
at risk for the disease have been strongly bolstered by newly published
study data showing growing acceptance of the drugs' indications for
patients at risk for dementia. Up to half of clinicians favor the use of
statins for treating patients at risk for developing cognitive
impairment and dementia due to vascular risk factors according to a new
study published in the Journal of Neurological Sciences (March 2005;
229-230: 147-150).

Researchers at the University of Leister surveyed 177 practising doctors
in rural England about the role of statins in the management of patients
at risk for developing cognitive impairment or with cognitive impairment
related to vascular disease or factors and found that nearly half (47%)
felt that statins have an important role in helping patients at risk of
developing cognitive impairment.

Nymox Pharmaceutical Corporation holds U.S. and global patent rights for
the use of statin drugs for the prevention and treatment of Alzheimers
disease (AD), including for patients at risk for AD because of
vascular-related risk factors or disease.

Statins are a class of cholesterol-lowering drugs that are the
biggest-selling prescription pills in pharmaceutical history with
estimated 2004 global sales of up to $26 billion. Alzheimer's disease is
the leading cause of dementia in the elderly, afflicting an estimated
4.5 million people in the U.S. alone.

The potential for the use of statin drugs to treat or reduce the risk of
Alzheimer's disease has been featured extensively in the media such as
New York Times (April 13, 2004), Fortune magazine (August 9, 2004),
Newsweek magazine (Jan 19, 2004), Los Angeles Times (June 22, 2003), and
The Wall Street Journal (April 17 and 18, 2002).

Numerous scientific and clinical studies have explored the potential
benefits of statin drugs to prevent or treat AD. Studies have shown up
to 70% reduction in AD incidence in individuals who use statin drugs. In
addition to recent studies presented at major medical conferences,
published peer-reviewed studies include, for example, International
Journal of Geriatric Psychiatry 2004; 19:327-32; Neuroepidemiology 2004;
23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet
2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci
Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in
the research and development of therapeutics and diagnostics, with a
particular emphasis on products targeted for the unmet needs of the
aging population. Currently Nymox has three products on the market, and
a healthy pipeline of drug and diagnostic products. The Company also has
several hundred patents and patent applications. Nymox has developed
AlzheimAlert™, a U.S. CLIA-certified test to aid in the diagnosis of
Alzheimer's disease. The Company has successfully completed two U.S.
Phase 1 and Phase 1-2 clinical trials for NX-1207, its drug for benign
prostatic hyperplasia (BPH). The Company markets NicAlert and TobacAlert
tests for measuring tobacco product exposure. Nymox has a number of
drugs in development for Alzheimer's disease, oncology, and infectious

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.


Contact Information

    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX